Novo Nordisk shares fall 5% after Trump vows weight-loss drug price cut

Core Viewpoint - Novo Nordisk's shares experienced a decline of approximately 5% following U.S. President Donald Trump's announcement regarding a price reduction for the company's leading weight-loss drug [1] Company Summary - Novo Nordisk is a Danish pharmaceutical company known for its best-selling weight-loss drug [1] - The company's stock performance was negatively impacted by the announcement from the U.S. President [1] Industry Summary - The announcement by the U.S. President indicates potential regulatory changes affecting drug pricing in the pharmaceutical industry [1] - Price reductions in popular medications could lead to increased scrutiny and adjustments in pricing strategies across the industry [1]